Noncoding Rnas as Novel Biomarkers in Pancreatic Cancer: what do we Know?

Previdi, Maria C.; Carotenuto, Pietro; Zito, Domenico; Pandolfo, Rosantony; Braconi, Chiara

doi:10.2217/fon-2016-0253

Cited by 65 publications

(45 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors also showed that ectopic over-expression of miR-181a increases the proliferation of PDAC cells by targeting the ATM gene, while the inhibition of miR-181a in combination with oxaliplatin treatment increased DNA damage and decreased cell viability. The clinical data, together with in vitro findings, strongly suggest the use of miR-181a as a biomarker to select patients responsive to FOLFIRINOX therapy [49,67].…”

Section: Pancreatic Carcinoma (Pdac)mentioning

confidence: 92%

The Pervasive Role of the miR-181 Family in Development, Neurodegeneration, and Cancer

Indrieri

Carrella

Carotenuto

et al. 2020

IJMS

Self Cite

116

110

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small noncoding RNAs playing a fundamental role in the regulation of gene expression. Evidence accumulating in the past decades indicate that they are capable of simultaneously modulating diverse signaling pathways involved in a variety of pathophysiological processes. In the present review, we provide a comprehensive overview of the function of a highly conserved group of miRNAs, the miR-181 family, both in physiological as well as in pathological conditions. We summarize a large body of studies highlighting a role for this miRNA family in the regulation of key biological processes such as embryonic development, cell proliferation, apoptosis, autophagy, mitochondrial function, and immune response. Importantly, members of this family have been involved in many pathological processes underlying the most common neurodegenerative disorders as well as different solid tumors and hematological malignancies. The relevance of this miRNA family in the pathogenesis of these disorders and their possible influence on the severity of their manifestations will be discussed. A better understanding of the miR-181 family in pathological conditions may open new therapeutic avenues for devasting disorders such as neurodegenerative diseases and cancer.

show abstract

Section: Pancreatic Carcinoma (Pdac)mentioning

confidence: 92%

The Pervasive Role of the miR-181 Family in Development, Neurodegeneration, and Cancer

Indrieri

Carrella

Carotenuto

et al. 2020

IJMS

Self Cite

116

110

View full text Add to dashboard Cite

show abstract

“…Apart from autoimmune antibodies, other novel markers including serum micro RNAs (miRNAs) signature have been reported to play a role in differentiating pancreatic carcinoma from AIP with high accuracy [26, 27]. MiRNA are endogenous small non-coding RNAs consisting of 19–25 nucleotides, which can interfere with gene transcription and/or translation, thus modulate the targeted gene expression[28].…”

Section: Discussionmentioning

confidence: 99%

Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin

Yan

Chen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Autoimmune pancreatitis (AIP) is a special type of chronic pancreatitis, which may be misdiagnosed as pancreatic carcinoma. This study aims to verify new biomarkers for AIP and propose a serological pattern to differentiate AIP from pancreatic adenocarcinoma with routinely performed tests. In this study, data of serum samples were collected and compared between 25 patients with AIP and 100 patients with pancreatic carcinoma. Receiver operating characteristic analysis and logistic regression was performed to evaluate the diagnostic effect of serum parameters in differentiating AIP from pancreatic carcinoma alone or in combination. Among several serum markers observed in the two groups, carbohydrate antigen 19–9 (Ca19-9), globulin, eosinophils and hemoglobin were selected as the independent markers. Serum levels of Globulin, Eosinophil percentage in AIP group were significantly higher than in pancreatic cancer group (P<0.05), while hemoglobin and tumor marker CA19-9 levels were lower (P <0.05). The combination of these markers identified patients with AIP with 92% sensitivity and 79% specificity, which indicated relatively high diagnostic value. Elevated serum eosinophils, globulin, together with decreased hemoglobin level can be used as a preoperative indicator for AIP and can help to initiate diagnosis of AIP in time.

show abstract

“…For instance, miR-16 and miR-196a together with CA19-9, constitute an effective set of first stage tumour markers. Indeed, some workers believe that miRNAs may have a role in assessing a patient's prognosis and their selection for treatment [26]. As an example, upon measuring circulating non-coding RNAs (ncRNAs) in cases of advanced PDAC, useful information can be gained, such as predicting the patient's response to chemotherapy.…”

Section: Nucleotidesmentioning

confidence: 99%